- Home
- FLYY vs TARA Comparison
FLYY vs TARA Comparison
Compare FLYY & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYY
- TARA
- Stock Information
- Founded
- FLYY 2025
- TARA N/A
- Country
- FLYY United States
- TARA United States
- Employees
- FLYY N/A
- TARA N/A
- Industry
- FLYY
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLYY
- TARA Health Care
- Exchange
- FLYY NYSE
- TARA Nasdaq
- Market Cap
- FLYY 119.2M
- TARA 126.5M
- IPO Year
- FLYY N/A
- TARA N/A
- Fundamental
- Price
- FLYY $4.85
- TARA $3.07
- Analyst Decision
- FLYY
- TARA Strong Buy
- Analyst Count
- FLYY 0
- TARA 7
- Target Price
- FLYY N/A
- TARA $20.67
- AVG Volume (30 Days)
- FLYY 351.1K
- TARA 488.2K
- Earning Date
- FLYY 01-01-0001
- TARA 08-05-2025
- Dividend Yield
- FLYY N/A
- TARA N/A
- EPS Growth
- FLYY N/A
- TARA N/A
- EPS
- FLYY N/A
- TARA N/A
- Revenue
- FLYY $4,660,283,000.00
- TARA N/A
- Revenue This Year
- FLYY N/A
- TARA N/A
- Revenue Next Year
- FLYY N/A
- TARA N/A
- P/E Ratio
- FLYY N/A
- TARA N/A
- Revenue Growth
- FLYY N/A
- TARA N/A
- 52 Week Low
- FLYY $4.68
- TARA $1.60
- 52 Week High
- FLYY $13.00
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- FLYY N/A
- TARA 53.15
- Support Level
- FLYY N/A
- TARA $2.77
- Resistance Level
- FLYY N/A
- TARA $3.23
- Average True Range (ATR)
- FLYY 0.00
- TARA 0.18
- MACD
- FLYY 0.00
- TARA 0.04
- Stochastic Oscillator
- FLYY 0.00
- TARA 88.02
About FLYY SPIRIT AVIATION HOLDINGS INC
Spirit Aviation Holdings Inc is committed to safely delivering the best value in the sky by offering an enhanced travel experience with flexible, affordable options. Spirit serves destinations throughout the United States, Latin America and the Caribbean with its all-Airbus Fit Fleet, one of the youngest and most fuel-efficient fleets in the U.S. Discover elevated travel options with exceptional value.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).